Enzolytics Inc (ENZC)

[foxi]

Great interview, thanks for the link!

47:36 Here's the section talking about where they are now and what the next steps are to getting clone-3 to market.

35:46 Very interesting why Cotropia thinks big pharma hasn't targeted covid immutable sites yet.




To me, the science in the presentation looks solid, as long as there's not a false equivalence fallacy in play. Let me explain.


I'm using covid as the example, though the same analysis applies to Cotropia's work with HIV, rabies, etc. This is also intentionally oversimplified for brevity.

Cotropia's hypothesis seems to be:

- If the blood of donors, who've previously had covid or a demonstrable immune reaction to the mRNA vaccine, contains antibodies to covid peptides;
- And administering clone-3 causes a second group's blood samples to contain those same antibodies;
- Then clone-3 could stop the people in the second group from getting covid.

ie If the blood samples can be made to 'look the same' when measuring the antibodies to covid peptides, clone-3 may thus produce the same (or greater) levels of immunity to covid as recovering from covid or having an immune response to the mRNA vaccines.

That's a big assumption. What other processes are involved in the body's ability to produce and maintain antibodies to covid peptides? Are there any advantages or side effects to getting antibodies from clone-3 vs mRNA vaccine vs wild covid? Are there other intermediate reactions which might also play a role in conditioning the body to produce and accommodate the antibodies and make the immunity longer-lasting, rather than just the final presence of antibodies?


To borrow and repurpose a quote from the Wikipedia false equivalence examples:

"They're both living animals that metabolize chemical energy. Therefore there's little difference between having a pet cat and a pet jaguar."

"They're both blood samples that contain antibodies to covid peptides. Therefore there's little difference between having those antibodies from a natural recovery from covid, a vaccine induced immune response, or from clone-3."



The research process is also interesting to note. The part of that discussion I'm highlighting starts at 40:32 and runs until 44:05.

Cotropia and team collect blood samples and test B-cells from people who test positive for covid via PCR, or who have been vaccinated and shown symptoms (immune reaction), 14 days after acute symptoms have terminated. They screen the blood to determine if these people have a presence of antibodies to the known covid peptides.

People who have recovered from covid or been vaccinated and demonstrated an immune response, but who do not have the expected B-cells believed to show immunity to covid, are screened out by the researchers. But are these excluded people actually also covid immune? Or are any of the patients with B-cells actually not covid immune but assumed to be? In other words, it may be necessary but not sufficient to make covid antibody presence match in the sample groups, to provide the expected immunity against covid.


So it's very important to get to the primate studies/other animal studies "to see if the hypothesis is correct", as Cotropia puts it. We need to see that clone-3 has the intended effect and not that some overlooked factors are also necessary for lasting and effective immunity. It's also important to know there won't be any side effects since the focus for now is on presence of antibodies, not the method by which they got there.

Very cool technology either way and it's exciting to have this glimpse into the details!